Mar 31, 2018
The Directors are pleased to present the thirty first (31th) Annual report and the audited financial statements of the Company for the financial year ended 31.03.2018.
FINANCIAL ANALYSIS
The following is the analysis of the standalone financial statements of the Company during the year under review.
(in Rs. Crores)
Particulars |
F.Y 2017.18 |
FY 2016.17 |
Total income from operations |
211.48 |
235.40 |
Profit from operations before interest, |
8.15 |
8.59 |
other income and exceptional items. |
||
Tax Expense |
2.51 |
3.27 |
Finance Cost |
9.24 |
8.46 |
Profit after tax |
5.94 |
5.31 |
Total Comprehensive Income |
5.64 |
4.96 |
Earnings per share (In Rs.) |
3.98 |
3.50 |
Appropriations:
Your Directors are pleased to recommend a dividend of Rs.I /- per equity share of Rs.10 each i.e 10% of the Equity Share Capital of the Company thereby appropriating an amount of Rs.1.41 Crores towards Dividend for the FY 2017.18, which is exclusive of the dividend distribution tax of Rs.28.85 Lakhs. The Company has not transferred any amount to General Reserves.
The register of members and share transfer books of the Company shall remain closed from 18th September 2018 to 22nd September 2018 (both days inclusive) for the purpose of payment of dividend for the FY 2017-18 and for the 31st Annual General Meeting scheduled to be held on 22.09.2018.
Share capital:
During the financial year under review, Rs.14,17,23,720/- comprising of 1,41,72,372 equity shares of Rs.10 each continues to be the issued and paid up capital of the Company.
During the financial year 2017.18, the Company has not issued any Equity Shares with differential voting rights, granted stock options nor issued sweat Equity Shares.
MANAGEMENT DISCUSSION AND BUSINESS ANALYSIS.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immuno Deficiency Syndrome) are supplied by Indian pharmaceutical firms. India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicine in UK.
Market Size
The Indian pharmaceutical sector was valued at US$ 33 billion in 2017. The country''s pharmaceutical industry is expected to expand at a CAGR of 22.4 per cent over 2015-2020 to reach US$ 55 billion. India''s pharmaceutical exports stood at US$ 17.27 billion in 2017-18 and are expected to reach US$ 20 billion by 2020.
Indian companies received 304 Abbreviated New Drug Application (ANDA) approvals from the US Food and Drug Administration (USFDA) in 2017. The country accounts for around 30 per cent (by volume) and about I0 per cent (value) in the US$ 70-80 billion US generics market.
India''s biotechnology industry comprising bio-pharmaceuticals, bio-services, bio-agriculture, bio-industry and bioinformatics is expected grow at an average growth rate of around 30 per cent a year and reach US$ 100 billion by 2025. Biopharma, comprising vaccines, therapeutics and diagnostics, is the largest sub-sector contributing nearly 62 per cent of the total revenues at Rs.12,600 crore (US$ 1.89 billion).
Investments
The Union Cabinet has given its nod for the amendment of the existing Foreign Direct Investment (FDI) policy in the pharmaceutical sector in order to allow FDI up to 100 per cent under the automatic route for manufacturing of medical devices, subject to certain conditions.
The drugs and pharmaceuticals sector attracted cumulative FDI inflows worth US$ 15.59 billion between April 2000 and December 2017, according to data released by the Department of Industrial Policy and Promotion (DIPP).
Some of the recent developments/investments in the Indian pharmaceutical sector are as follows:
- During 2017-18, Indian pharmaceutical sector witnessed 46 merger & acquisition (M&A) deals worth US$ 1.47 billion.
- The exports of Indian pharmaceutical industry to the US will get a boost, as branded drugs worth US$ 55 billion will become off-patent during 2017-2019.
Government Initiatives
Some of the important initiatives taken by the government to promote the pharmaceutical sector in India are as follows:
- The National Health Protection Scheme is largest government funded healthcare programme in the world, which is expected to benefit 100 million poor families in the country by providing a cover of up to Rs.5 lakh (US$ 7,723.2) per family per year for secondary and tertiary care hospitalisation. The programme was announced in Union Budget 2018-19.
- In March 2018, the Drug Controller General of India (DCGI) announced its plans to start a single-window facility to provide consents, approvals and other information. The move is aimed at giving a push to the Make in India initiative.
- The Government of India is planning to set up an electronic platform to regulate online pharmacies under a new policy, in order to stop any misuse due to easy availability.
- The Government of India unveiled âPharma Vision 2020'' aimed at making India a global leader in end-to-end drug manufacture. Approval time for new facilities has been reduced to boost investments.
- The government introduced mechanisms such as the Drug Price Control Order and the National Pharmaceutical Pricing Authority to deal with the issue of affordability and availability of medicines.
Road Ahead
Healthcare spending in India is expected to increase at 9-12 per cent CAGR between 2018-22 to US$ 50-55 billion, driven by increasing consumer spending, rapid urbanisation, and raising healthcare insurance among others.
Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as cardiovascular, anti-diabetes, antidepressants and anti-cancers, which are on the rise.
The Indian government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the Indian pharmaceutical companies.
BUSINESS OPERATIONS:
Turnover and Net profit:
Yjur company has registered a total revenue of Rs.211.48 Crores for the financial year ended 31.03.2018 as against Rs. 235.40 Crores during the previous year. The drop in the turnover is due to the effect of implementation of GST during the financial year and also due to changes in the presentation of Profit & Loss Account as per IND AS.
Rs.8.15 Cr was the Profit before tax (PBT) of the Company for the financial year ended 31.3.2018.
The Company has registered a net profit of Rs.5.93 Crores for the year ended 31.03.2018 as against the net profit of Rs.5.31 Crores during the previous year.
The company has recorded an EPS of Rs.3.98 per equity share of Rs.10 each as against Rs.3.50 during the previous year.
Formulations Business:
The formulations business of the Company has contributed a revenue of Rs.103.10 Crores during FY 2017.18 as against the revenue of Rs.106.31 Crores during FY 2016.17.
Turnover from the export of formulations during FY 2017.18 is at Rs.52.97 Crores as against Rs.61.43 crores during FY16.17.
Domestic sales of formulations mainly constituting branded formulations has contributed a revenue of Rs.50.12 Crores during FY 2017.18 as against a revenue of Rs.44.88 Crores during FY 2016.17.
Bulk Drugs Business:
As against the total revenue of '' 120.49 Crores from the bulk drugs business during FY 2016.17, the company has recorded a sales revenue of Rs.103.17 Crores from bulk drugs for the financial year 2017.18. Revenue from export of API products has resulted in a turnover of Rs.60.33 Crores and domestic sales of the said products has yield a revenue of Rs.42.85 Crores.
Diabetic and cardiac drugs of the Company continues to be the major revenue earners of the Company, from both domestic and export markets during the financial year.
Export Business:
The Company has recorded export sales of Rs.113.29 Crores as against Rs.121.67 Crores recorded during the previous financial year.
Domestic Business:
The Company has recorded a revenue of Rs.92.97 Crores from its domestic business for the financial year 2017.18 as against the domestic revenue of Rs.105.13 crores during 2016.17.
NEW PROJECTS:
During the year under review, Bal Pharma Ltd has acquired 100% stake and management control of Golden Drugs Private Ltd, an Udaipur, Rajasthan based private limited Company involved in the manufacture of bulk drugs and intermediates. The total cost of acquisition is Rs.14 Crores which involves purchase of 100% shareholding of the Company with a purchase consideration of '' 20.66/- per shares and also towards repayment of all the past liabilities of the Company. With this acquisition, Bal Pharma Ltd aims to increase its production capacity by at least 20% and also enter into unexplored API markets, both domestic and international.
In addition to this, the Company assesses the future infrastructure requirements and continuously invests in the same on need basis.
AUDIT COMMITTEE:
Audit Committee, a subcommittee of the Board consists of Mr.Pramod Kumar.S, Dr.G.S.R Subba Rao, Mrs. Sarika Bhandari, Independent Directors of the Company.
Audit Committee of the Company continues to discharge its duties as per the provisions of Section 177 of the Companies Act, 2013 and also SEBI (LODR) Regulations, 2015.
AUDITORS AND AUDITORS REPORT:
a) Statutory Auditors:
Messers NSVM & Associates, Chartered Accountants (FRN # 0I0072S) were appointed as Statutory Auditors of the Company from the conclusion of 30th Annual General Meeting held on 22.09.2017 up to the conclusion of 35th Annual General Meeting i.e for a period of 5 years.
There are no qualifications or adverse remarks or observations by the Statutory Auditors in their report issued for the financial year 2017.18.
b) Cost Auditors:
Mr.M.R Krishna Murthy , Cost accountant,(FCMA # 7568) was reappointed as the Cost Auditor of the Company for the financial year 2018-19, to conduct cost audit of the cost records maintained by the Company.
c) Secretarial Auditors:
Mr.Parameshwar G Bhat, Practising Company Secretary ( CP # 11004) were appointed as the Secretarial Auditor of the Company for the financial year 2017.18. No adverse comments or remarks were made by the auditor in his report for the F.Y 2017.18, which is annexed to this report.
d) Internal Auditors:
Messers Bharath & Co, Chartered Accountants, (MRN # 240163) were appointed as the Internal Auditors of the Company for the FY 2017.18 and the internal audit reports issued by them were periodically reviewed by the Audit Committee and the management of the Company is appraised about the observations of the internal auditor and on corrective actions, if any, that needs to be taken.
Risk Management:
The Risk Management Committee of the Company comprising of the functional heads of the Company will submit its periodical report to the Board of Directors on the measures to be taken for mitigation of potential risk factors that may affect the business of the Company.
The Risk Management Policy implemented by the Company which is designed to enable risks to be identified, assessed and mitigated appropriately, is available on the website of the Company i.e www. balpharma.com.
Internal Control System and its Adequacy:
Your Company has an adequate system of internal controls with clearly defined authority limits. Internal controls ensure that the Company''s assets are protected against loss from unauthorised use or disposition and all transactions are authorised, recorded and reported in conformity with generally accepted accounting principles. The Company has in place adequate internal financial controls with respect to Financial Statements. These systems are designed to ensure accuracy and reliability of accounting data, promotion of operational efficiency and adherence to the prescribed management principles. These policies are periodically reviewed to meeting business requirements.
Directors responsibility statement.
In compliance with the provisions of Section 134(5) of the Companies Act,20l3, your Directors wish to confirm,
a) That in preparing the annual accounts, all the applicable accounting standards had been followed along with proper explanation relating to material departures.
b) That the Directors had selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the Financial year and of the profit and loss of the Company for that period.
c) That the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the act for safeguarding the assets of the Company and for preventing / detecting fraud and other irregularities.
d) That the Directors had prepared the annual accounts on a going concern basis.
e) That the Directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively.
f) That the Company had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.
Related party Transactions:
All contracts /arrangements / transactions entered by the Company during the financial year with related parties were in ordinary course of business and at arms length basis. During the year, the Company has not entered into any contract/arrangement/transaction with the related parties that could be considered material, as per the policy of the Company on materiality of related party transactions.
There were no materially significant related party transactions which could have potential conflict with the interests of the Company at large.
The Company''s policy on the related party transactions as approved by the Board can be assessed from the website i.e www.balpharma.com.
For disclosure relating to the related party transactions, please refer to note # 34 of the financial statements.
Subsidiary, Joint Venture and Associate Companies:
During the year under review, the following Companies listed below continues to be the subsidiaries, joint ventures or associates of Bal Pharma Ltd. A report on the financial performance of each of the subsidiaries, joint ventures or associate companies as per section 129(3) of the Companies Act, 2013 is provided in Annexure 1 to the Board''s report and hence not repeated here for the sake of brevity.
Sl No |
Name of the Company/LLP |
Nature of Business |
% of stake with Bal Pharma, as on 31.03.2018 |
01 |
Lifezen Healthcare Private Limited |
Marketing of OTC products |
50.50% |
02 |
Bal Research Foundation |
Research and Development |
80% |
03 |
Balance Clinics LLP |
Diabetic care clinics. |
80% |
04 |
Golden Drugs Private Limited |
Manufacturing of API''s |
100% |
Secretarial Standards:
Secretarial Standards i.e SSI & SS2 relating to the meetings of Board of Directors and General meetings, respectively have been duly followed by the Company.
Directors and Key Managerial Personnel (KMPâs):
The Nomination and Remuneration Committee has recommended for reappointing Dr.Subba Rao Prasanna as whole time Director of the Company for a further period of 2 years. His reappointment is being considered at the ensuing Annual General Meeting by a special resolution.
The Company has received declarations from all the Independent Directors confirming that they meet the criteria of independence, as prescribed under Section 149(6) of the Companies Act, 2013.
The Company has devised a policy for familiarization of Independent Directors on their roles, rights, responsibilities with the Company and the said policy is available on our website.
The Company has also in place a Policy for nomination and remuneration of KMP''s, Senior Management personnel and Directors of the Company, which is in compliance with Section 178 of the Companies Act, 2013.
The Company has devised a policy for performance evaluation of the Board, committees and Individual directors. The evaluation process inter alia considers attendance of Directors at Board and Committee meetings, acquaintance with business, communication within Board members, effective participation, domain knowledge, compliance with the internal code of conduct, vision and strategy.
The Board carried out annual performance evaluation of itself, Committees, Individual Directors and Chairman. The performance of each committee is evaluated based on the reports of evaluation received from the respective committees.
Report on performance evaluation of the individual Directors was reviewed by the Chairman and feedback was given to the Directors. Details of Board and Committee Meetings held during the year is disclosed in the Corporate Governance Report.
Vigil Mechanism:
The vigil mechanism of the Company which also incorporates Whistle Blower Policy as prescribed by SEBI(LODR) Regulations, 2015 includes compliance task force comprising of senior executives of the Company. The policy of whistle blower is available on our website.
Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outflow:
As per the provisions of Section 134 of the Companies Act, 2013, details relating to the conservation of energy, technology absorption, foreign exchanges earnings and outflow are given as Annexure -3 to this report.
Corporate Governance:
The Company is committed to maintaining highest standards of Corporate Governance requirements set out by the Securities and Exchange Board of India. A detailed report on the corporate governance system and practises of the Company along with a certificate from the practising Company secretary confirming to the compliance with the corporate governance requirements, are given in a separate section of this report.
Particulars of Loans given, investments made, Guaranteeâs given or security provided by the Company.
The Company makes investments and trade advances to its subsidiaries for their business purpose. Details of loans, investments and advances covered under Section 186 of the Companies Act, 2013, form part of the notes to the financial statements provided in this annual report.
Material Changes and Commitments affecting the financial position of the Company between the end of the financial year and up to the date of this report.
There have been no material changes or commitments affecting the financial position of the Company between the end of the financial year and date of this report. There has been no change in the nature of business or constitution of the Company.
Extract of the Annual Return:
In accordance with Section 134 (3) (a) of the Companies Act, 2013, an extract of the Annual return of the Company for the financial year 2017-18 in Form MGT-9 is annexed to this report as Annexure-5.
Corporate Social Responsibility:
As per the provisions of Section 135 of the Companies Act,20I3, the Company has constituted a CSR committee with the following Composition.
1.Dr.G.S.R Subba Rao - Chairman
2.Mr.Pramod Kumar.S - Member
3.Dr.S.Prasanna - Member
4.Mr.Shailesh Siroya - Member
The Committee has formulated an Corporate Responsibility policy which recommends the activities to be undertaken by the Company, as specified in Schedule VII of Companies Act,20I3. A copy of the said policy is available on the website i.e www.balpharma.com. The Committee has not recommended any CSR budget for the financial year 20I8.I9, due to inadequate profits
Human Resources:
Human resources of the Company has major share in the growth and development of the Company. The Company continues to hire new talent in order to keep pace with the new projects and initiatives undertaken. The Management of the Company aims to strengthen its employee relations through progressive people management.
Board Evaluation:
The Board of Directors of the Company has carried out annual performance evaluation of its own performance, its Committees and individual Directors at their meeting held on I4.02.20I8. The Board has expressed satisfaction over the overall functioning of the Board members and their committees which are in line with the objectives and goals of the Company.
Listing with Stock Exchanges:
The Equity Shares of the Company continued to be listed on BSE Limited, Mumbai and National Stock Exchange of India Ltd, Mumbai and the Company has paid the annual listing fees for F.Y 2018-19 to the exchanges.
CEO & CFO certification:
The CEO and CFO of the Company in their submission to the Board have confirmed that the annual financial statements presents a true and fair view of the Company''s affairs and do not omit any material facts, which may make the statements or figures contained therein either misleading or false.
Insurance Coverage:
The Management of the Company wishes to confirm that all the movable, immovable and current assets of the Company are covered with comprehensive and adequate insurance cover.
Credit Rating:
The discipline with which the Company conducts its financial transactions is reflected in the BBB(stable) rating given by the credit rating agency ICRA for the financial year 2017-18. The Management of the Company aims at further improving its credit rating during the current financial year.
Disclosure under the sexual harassment of Women at work place (Prevention, Prohibition and Redressal) Act, 2013:
The Company has in place an anti-sexual harassment policy on lines with the requirements of the sexual harassment of women at the work place (Prevention, Prohibition and Redressal) Act,20I3. All the employees of the Company either they are permanent, contractual, temporary or trainees, are covered by the policy.
The following is the summery of the Complaints regarding sexual harassment, received and redressed during the financial year 2017-18.
Number of Complaints received during the year : Nil
Number of Complaints resolved : NA
Number of Complaints pending at the end of the year : NA
Particulars of Employees:
Disclosures pertaining to remuneration and other details as required under Section 197(12) of the Companies Act, 2013, read with Rules 5(1), 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are attached as âAnnexure 4â to this report.
General Information:
Your Directors reports that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review.
1 Details relating to the deposits covered under Chapter V of the Companies Act, 2013.
2 Issue of equity shares with differential voting rights with respect to dividend, voting etc.
3. Issue of shares (including sweat equity shares) to the employees of the Company under any scheme.
4. Neither the Managing Director nor the whole time Directors of the Company receive any remuneration or commission from any of its subsidiaries.
5. No significant or material orders were passed by the regulators or courts or tribunals which impacts the going concern status of the Company and its operations in future.
6. No fraud has been reported by the Auditors to Audit Committee or the Board during the year.
Appreciation:
Your Directors express their gratitude to the Company''s customers, shareholders, employees, business partners'' viz. distributors, suppliers, medical professionals, Company''s bankers, financial institutions including investors for their valuable, sustainable support and co-operation.
Mar 31, 2016
To the Members,
The Directors are pleased to present the Twenty Ninth (29th) Annual Report and the Company''s Audited Financial Statements for the Financial Year ended 31.03.2016.
FINANCIAL RESULTS
The following is the summary of the Company''s Consolidated financial performance during the year under review.
(Rs, in Crores)
Particulars |
FY 2015-16 |
FY 2014-15 |
Total Income from operations |
198.32 |
187.15 |
Profit from operations before Interest other income and exceptional items. |
7.84 |
10.08 |
Tax expense |
2.39 |
1.18 |
Finance cost |
6.48 |
6.52 |
Profit After Tax |
0.26 |
3.55 |
Profit After Taxes and Minority Interest and share of profit /loss of associates |
1.40 |
3.62 |
Earnings per Share (in Rupees) |
1.09 |
2.83 |
Note : Previous year''s expenses have been regrouped wherever necessary to confirm to this year''s classification.
2. DIVIDEND & APPROPRIATIONS
Your Directors are pleased to recommend dividend of Rs, 1.00/- (i.e 10%) on each Equity Share of Rs, 10/- , thereby absorbing an amount of Rs, 1.41 crores excluding Dividend Distribution Tax of Rs, 28.85 Lakhs.
3. SHARE CAPITAL:
The Company has made the allotment of 13,00,000 Equity Shares of Rs, 10/- each on preferential basis with each share carrying a premium of Rs, 52/-. With this allotment, the Paid-up Equity Share Capital of the Company has increased to Rs, 14,17,23,720/- divided into 1,41,72,372 Equity Shares of Rs, 10/- each.
During the period under review, the Company has not issued shares with differential voting rights nor granted stock options nor Sweat Equity Shares.
4. MANAGEMENT DISCUSSION AND BUSINESS ANALYSIS: Indian Pharmaceutical Industry scenario and opportunities:
India continues to be the global manufacturing hub for the pharmaceuticals during the financial year 2015.16. Presently there are 10,500 manufacturing units and over 3,000 Pharmaceutical Companies in India, and still growing at an exceptional rate. India has about 1,400 WHO GMP approved manufacturing units.1,105 CEP accredit ions , more than 950 TGA approvals and 584 sites approved by the USFDA. Globally more than 90 per cent of formulations approvals for Anti-retroviral (ARVs), Anti-tubercular & Anti-malarial (WHO pre-qualified) have been granted to companies present in India. Manufacturing costs in India are approximately 35-40 percent less than those in the US due to low installation and manufacturing costs. Qualified manpower , availability of raw materials and a huge domestic market for growth are some of the contributing factors for this scenario. India ranks amongst the top global generic formulation exporters in volume terms.
India''s exports of pharma and drugs stood at US$ 16.8 bn. India exports all forms of pharmaceuticals from APIs to formulations, both in modern medicine and traditional Indian medicines. The country''s pharmaceutical industry accounts for about 1.4 per cent of the global pharmaceutical industry in value terms and 10 per cent in volume terms.
Bal Pharma Limited during the year under review has aimed at consolidating its position in Indian market by advancing its project on modernizing and expansion of its manufacturing capabilities, which is expected to be completed by December 2017. Once the enhanced production capability is made available to the Company, it is expected to meet the demand of its signature products in Cardiology, Diabetology, Analgesics, Antipyretics, Antibiotic, Anti histamine, IV fluids, Nutrition supplements etc both in domestic and international markets.
Lifezen healthcare Private Limited, an Over The Counter (OTC) products marketing Company floated by Bal Pharma Limited as its Subsidiary has launched 2 new products in Indian OTC market and the said products has received encouraging response from the market. Even through the Subsidiary is yet to break even in its business; it has made its presence felt in OTC market and aiming at an profitable business model in near future.
5. BUSINESS OPERATIONS
(i) Turnover and Net profit:
During the Financial Year 2015-16, your Company has achieved a gross standalone turnover of Rs, 201.82 Crores as against Rs, 190.67 Crores achieved during the previous Financial Year, thus registering a top line growth of 5%. .
The Net Profit After Tax of the Company during the financial year 2015-16 stands at Rs, 2.81 Crores as against the Net Profit of Rs, 4.02 Crores achieved in the previous financial year 2014-15.
(ii) Formulations Business:
The Formulations Business of the Company has contributed a total revenue of Rs, 111.03 Crores, during the FY 2015-16 as compared to Rs, 115.40 Crores, during F Y 2014-15.
The turnover from export of formulations during the year under review stands at Rs, 61.51 Crores as against Rs, 73.51 Crores achieved during the previous financial year. This drop in revenues is due to sluggish economy in overseas markets.
In the domestic market, Branded formulations of the Company, consisting of mainly Diabetic, Gynaecology and Cardiac drugs have contributed to revenue of Rs, 36.00 Crores during the year under review as against Rs, 22.49 crores achieved during the previous year.
(iii) Bulk Drug Business:
Bulk Drug Business continue to show its momentum in sales with a revenue of Rs, 87.31 Crores during the year under review as compared to Rs, 75.13 Crores achieved during the previous financial year, thereby registering a growth of 10.7%.
Exports sales of bulk drugs during the year under review stands at Rs, 53.60 Crores as against Rs, 48.01 crores registered during the previous financial year.
Domestic sales of the bulk drugs have registered an revenue of Rs, 33.70 Crores as against the revenue of Rs, 27.24 Crores registered during the previous financial year.
(iv) Export Performance:
The overall export sales of the Company during the year under review has recorded a turnover of Rs, 115.11 Crores as against revenue of Rs, 121.53 Crores achieved during the previous financial year.
Revenues from the export sales continue to consistently dominate the Companies overall turnover.
(v) Domestic Performance:
Revenue from domestic sales has registered a turnover of Rs, 82.76 Crores as compared to Rs, 64.46 Crores achieved during 2014-15, there by registering an growth of 22% .
Diabetic and Cardiac drugs of the Company continue to prove their dominance in revenue earnings in Indian markets.
7. AUDIT COMMITTEE:
The Audit Committee, a sub-Committee of Board consists of Dr. G.S.R Subba Rao, Independent Director, Mr. Shrenik Siroya, Non-Executive Director, Mr. Pramod Kumar S, Independent Director and Mrs. Sarika Bhandari, Independent Director.
Mr. Pramod Kumar S was appointed as Chairman of the Committee on 10.02.2016 in place of Dr. G.S.R Subba Rao, who resigned from the Chairmanship of the Committee citing personal reasons. The Audit Committee has been discharging its duties as per the provisions of SEBI (LODR) Regulations, 2015 and as per Section 177 of the Companies Act, 2013.
8. AUDITORS AND AUDITORS REPORT :
a. Statutory Auditors:
Messrs T.D Jain and D I Sakaria , Chartered Accountants were appointed as Statutory Auditors of the Company from Financial Year 2015-16 to 2017-18 i.e., for the period of 3 years, to hold office from the conclusion of 28th Annual General Meeting held on 22nd September, 2015 until the conclusion of 31st Annual General Meeting, subject to ratification of their appointment at every subsequent Annual General Meeting..
There are no qualifications or reservations or adverse remarks by the Statutory Auditors in their report.
b. Cost Auditors:
Pursuant to the provisions of Section 148 of the Companies Act, 2013, the Company has appointed Mr. M.R Krishna Murthy, Cost Accountant as Cost Auditor for conducting audit of cost records of the Company, for the Financial Year 2015-16.
c. Secretarial Auditors:
Pursuant to the provisions of Section 204 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed Mr. Parameshwar G. Bhat, Practising Company Secretary to conduct Secretarial Audit of the Company for the Financial Year 2015-16. The Secretarial Audit report for the Financial Year 2015-16 is annexed to this report as Annexure 2. Certain non material observations made by Secretarial Auditor in his report have been suitably addressed by the Management with corrective actions, wherever necessary.
d. Internal Auditors:
Messrs Abhishek Jain and Dheeraj Bafna, Chartered Accountants were appointed as Internal Auditors of the Company for the financial year 2015-16 and their Reports on Internal Audit were periodically reviewed by the Audit Committee and recommends to the Board for its noting. The Internal Audit Reports do not contain any qualifications, reservations or adverse remarks.
9. RISK MANAGEMENT:
The Risk Management Committee of the Company consisting of the Functional heads and Company Secretary of the Company will submit its periodical report to the Board of Directors of the Company on the measures taken for mitigation of potential risk factors.
The Risk Management Policy devised and implemented by the Company is available on the website i.e www.balpharma.com.
10. INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY:
Your Company has an adequate system of internal controls with clearly defined authority limits. Internal controls ensure that the Company''s assets are protected against loss from unauthorized use or disposition and all transactions are authorized, recorded and reported in conformity with Generally Accepted Accounting Principles. These systems are designed to ensure accuracy and reliability of accounting data, promotion of operational efficiency and adherence to the prescribed management policies. These policies are periodically reviewed to meet current business requirements.
11. DIRECTORS'' RESPONSIBILITY STATEMENT
In compliance with the provisions of Section 134(5) of the Companies Act, 2013, your Directors wish to confirm:
a) that in preparing the Annual Accounts, all the applicable Accounting Standards have been followed along with proper explanation relating to material departures;
b) that the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the Financial Year and of the Profit and Loss of the Company for that period.
c) that the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing/detecting fraud and other irregularities;
d) that the Directors have prepared the annual accounts on a going concern basis.
e) that the Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively.
f) that the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.
12. CONTRACTS AND ARRANGEMENTS WITH RELATED PARTIES :
All contracts/arrangements/transactions entered by the Company during the financial year with related parties were in the ordinary course of business and on arm''s length basis. During the year, the Company had not entered into any contract/arrangement/ transaction with related parties that could be considered material
i.e., exceeding 10% of the annual consolidated turnover of the Company, as defined in SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.
The Company''s Policy on the Related Party Transactions as approved by the Board can be accessed from our website
i.e www.balpharma.com.
Please refer to the note #34 to the financial statements, which sets out related party disclosures.
13. SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES:
During the year under review, the following Companies listed below are Company''s Subsidiaries, Joint Ventures or Associate Companies. A report on the performance and financial position of each of the Subsidiaries, Associates, Joint Venture companies as per Companies Act, 2013 is provided as Annexure 1 to the Board''s Report and hence not repeated here for the sake of brevity.
Sl. No. |
Name of the Company/LLP |
Nature of Business |
% of stake as on 31.03.2016 |
01 |
Lifezen Healthcare Private Limited |
Marketing of Over the counter (OTC) products |
50% |
02 |
Bal Research Foundation |
Research and Development in Pharma and health care. |
80% |
03 |
Balance Clinics LLP |
Diabetic care clinics |
80% |
14. DIRECTORS AND KEY MANAGERIAL PERSONNEL (KMP):
In accordance with the provisions of the Companies Act, 2013 and the Articles of Association of the Company, Mr. Shrenik D Siroya, Non Executive Director of the Company retires by rotation at the Annual General Meeting and being eligible offers himself for reappointment.
As per Section 196,197 and Schedule V of the Companies Act,2013, Dr.S.Prasanna is being reappointed as the Whole time Director of the Company for a period of 2 years w.e.f 1.10.2016 to 30.9.2018.
The Company has received declarations from all the Independent Directors of the Company confirming that they meet the criteria of independence as prescribed under Section 149(6) of the Companies Act, 2013.
The Company has devised a Policy for familiarization of independent Directors with the Company, their roles, rights, responsibilities in the Company etc and the same is uploaded on the website of the Company i. e www.balpharma.com.
The Company also has in place a Policy for Nomination and remuneration of KMP''s, Senior Managerial personnel and Directors of the Company, which is in compliance with Section 178 of the Companies Act, 2013. The said Policy is available on the website of our Company.
15. VIGIL MECHANISAM:
The vigil mechanism of the Company, which also incorporates Whistle Blower Policy as per the SEBI (LODR) Regulations, 2015, includes compliance task force comprising of Senior Executives of the Company. The complete text on the vigil mechanism and Whistle Blower Policy can be accessed from our website i.e., www.balpharma.com.
16. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND FOREIGN EXCHANGE OUTGO:
As per provisions of Section 134(m) of the Companies Act, 2013, read with the rule 8 of the Companies (Accounts) Rules, 2014, details relating to the Conservation of Energy and Technology Absorption and Foreign Exchange Earnings and Outflow are given in Annexure-3, which forms part of the Board''s Report.
17. PARTICULARS OF EMPLOYEES:
Information as per Rule 5(1) of Chapter XIII of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is enclosed as an Annexure - 5 to this report.
18. CORPORATE GOVERNANCE AND ADDITIONAL INFORMATION TO SHARE HOLDERS:
A detailed report on the Corporate Governance System and practices of the Company are given in a separate section of this Annual Report. Detailed information for the shareholders is given in Additional Shareholders information section.
19. PARTICULARS OF LOAN GIVEN, INVESTMENTS MADE, GUARANTEES GIVEN OR SECURITY PROVIDED BY THE COMPANY:
The Company has not given any loan or guarantees covered under the provisions of Section 186 of the Companies Act, 2013.
20. MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY BETWEEN END OF THE FINANCIAL YEAR AND THE DATE OF THE REPORT:
There were no material changes and commitments between the end of the financial year and the date of the Report, which affect the financial position of the Company.
21. EXTRACT OF ANNUAL RETURN:
Extract of the Annual Return of the Company for the Financial Year 2015-16, in Form MGT-9 is annexed to this report as Annexure - 4.
22. CORPORATE SOCIAL RESPONSIBILITY:
The Board has constituted a Corporate Social Responsibility Committee consisting of Dr. G.S.R Subba Rao, Mr. Pramod Kumar
S, Dr. S. Prasanna and Mr. Shailesh Siroya as its members.
The Committee has formulated a Corporate Social Responsibility (CSR) Policy and the Board has approved the Policy for its implementation. The CSR Policy may be accessed from our website i.e., www.balpharma.com .
Due to delay in suitable planning of the CSR activities, the Company could not spend any amount towards Corporate Social responsibility for the year ended 31.03.2016.
23. HUMAN RESOURCES:
The human resources of the Company continue to contribute its share in the growth of the Company. Human Resource agenda of the Company for the year continued to focus on building a talent pipeline, enhancing individual and organizational capabilities for future readiness, driving greater employee engagement, and strengthening employee relations through progressive people management.
There was no complaint lodged by any woman employee under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, with the Company during the period under report.
24. ANNUAL BOARD EVALUATION:
Pursuant to the provisions of the Companies Act, 2013 and Listing Regulations, the Board has carried out an annual performance evaluation of its own performance, its Committee''s and the Directors individually. The manner in which the evaluation has been carried out has been explained in the Corporate Governance Report
25. LISTING WITH STOCK EXCHANGES:
The Securities and Exchange Board of India (SEBI), on September
2, 2015, issued SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the aim to consolidate and streamline the provisions of the Listing Agreement for different segments of capital markets to ensure better enforceability. The said regulations were effective December 1, 2015. Accordingly, all listed entities were required to enter into the Listing Agreement within six months from the effective date. The Company entered into revised Listing Agreement with BSE Limited and the National Stock Exchange of India Limited, during November 2015.
The Company has paid the Annual Listing Fees for the year 201617 to National Stock exchange of India Limited (NSE) and BSE Limited (BSE) where the Company''s Shares are listed.
26. CEO & CFO CERTIFICATION:
The Board has acknowledged that Managing Director as the CEO of the Company and DGM Finance and Accounts as the CFO for the purpose of compliance under the Listing Regulations. The CEO and CFO have certified to the Board, in terms of Regulation 33(2) of SEBI (LODR) Regulations, 2015, that the financial statements present a true and fair view of the Company''s affairs and do not omit any material facts which may make the statements or figures contained therein misleading.
27. INSURANCE COVERAGE:
The Board of Directors reports that your Company has adequate and comprehensive insurance cover on all the movable and immovable assets of the Company.
28. CREDIT RATING:
The Company''s financial discipline is reflected in the BBB (stable) rating given by ICRA for the Companies borrowings, both for term loan and working capital for the financial year 2015-16 which is a notch above the previous year''s credit rating of BBB - . The Company looks forward to further improve its credit rating during the Financial Year 2016-17.
29. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:
The Company has in place an Anti Sexual Harassment Policy in line with the requirements of the Sexual Harassment of Women at the Workplace (Prevention, Prohibition & Redressal) Act, 2013. Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy.
The following is a summary of sexual harassment complaints received and disposed off during the year 2015-16:
No. of complaints received : NIL No. of complaints disposed off : NIL
30. GENERAL:
Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review.
1. Details relating to deposits covered under Chapter V of the Act.
2. Issue of equity shares with differential rights as to dividend, voting etc.
3. Issue of shares (including sweat equity shares) to the employees of the Company under any scheme.
4. Neither the Managing Director nor the whole time Directors of the Company receive any remuneration or commission from any of its subsidiaries.
5. No significant or material orders were passed by the regulators or courts or tribunals which impact the going concern status and Company''s operations in the future.
31. APPRECIATION:
Your Directors wish to express their sincere appreciation on significant contributions made by the employees through their dedication, hard work and commitment. Your Directors also place on record their sincere thanks on the trust reposed on the Company by the medical fraternity and the patients. We also acknowledge the support extended by Canara Bank, Punjab National Bank, EXIM Bank, Corporation Bank and other financial institutions, government agencies, shareholders and investors at large. We look forward to the continued support from all the quarters in our endeavor to help people lead healthier lives.
For and on behalf of the Board of Directors
Bengaluru Dr. S. Prasanna Shailesh D Siroya
10th August 2016 Whole Time Director Managing Director
Mar 31, 2014
Dear Members,
The Directors have pleasure in presenting the 27th Annual Report
together with the Audited Accounts of the Company, for the financial
year ended on 31st March, 2014. As notified by MCA vide Circular No.
1/19/2013-CL-V dated 04.04.2014, we have followed the provisions of
Companies Act, 1956, in the preparation of this report.
1. FINANCIAL RESULTS
(Rs. in Crores)
Particulars FY 2013-14 FY 2012-13
1) Total Income from operations 182.01 150.25
2) Earnings before Interest , Tax , 18.53 17.88
Depreciation & Amortisation
Less :
Depreciation & Amortisation 4.74 4.81
Finance cost 7.16 7.98
Profit before taxation and prior
period adjustments. 6.63 5.09
Less :
3) Current Tax (Net) 1.55 -
4) Deferred Tax 0.01 0.82
5) Extra Ordinary / Non Recurring items - -
6) Prior year Adjustments (0.01)
7) Net Profit 5.07 4.28
Add :
8) Profit & loss account balance at the 15.16 11.80
beginning of the year
9) Profit /(Loss) made available for 20.23 16.08
appropriation
Less :
10) Proposed Dividend on Equity Shares 1.11 0.79
11) Tax on Dividend 0.19 0.13
12) Balance Carried to Balance sheet 18.93 15.16
Note : Previous year''s figures have been regrouped wherever necessary
to confirm to this year''s classification.
2. DIVIDEND & APPROPRIATIONS
Your Directors are pleased to recommend a payment of Dividend of Re.
1.00/- (i.e 10%) on each Equity Share of Rs. 10/- each, thereby
absorbing an amount of Rs. 1.11 crores excluding Dividend Distribution
Tax of Rs. 0.19 crores. The balance amount of profit is retained as
surplus in the Statement of Profit and Loss, forming part of Reserves
and Surplus.
3. BUSINESS OPERATIONS
(i) Turnover and Net profit:
During the financial year 2013-14, your Company has achieved highest
ever gross turnover of Rs. 182.01crores as against Rs. 150.25 crores
achieved during the previous financial year, thus registering a good
growth of 21.14%.
The net profit after tax of the Company during the financial year
2013-14 stands at Rs. 5.07 Crores as against the net profit of Rs. 4.28
crores achieved in the previous financial year, 2012-13.
(ii) Formulations'' Business:
The turnover from export of formulations during the year under review
stands at Rs. 72.24 crores as against Rs. 48.47 crores achieved during
the previous financial year, thus registering an excellent growth of
49%. The growth in export sales of formulations was due to high value
orders received from overseas markets, especially markets like Latin
America, Africa, etc.
In the domestic market, Branded formulations of the Company, consisting
of mainly Diabetic, Gynaecology and Cardiac drugs have contributed to a
revenue of Rs. 24.93 crores during the year under review as against Rs.
24.63 crores achieved during the previous year.
During the year revenue from the sale of Export formulation comprising
of Branded Items surpassed the revenue from the sale of Bulk Drugs.
(iii) Bulk Drug Business:
Bulk drug business continue to grow, with a revenue of Rs. 62.25 crores
during the year under review as compared to Rs. 54.86 crores achieved
during the previous financial year, thereby registering a double digit
growth of 13.47%. Exports of bulk drug during the year under review
stands at Rs. 35.42 crores as against Rs. 37.57 crores during the
previous financial year. Thus, during the year under review, while
export sales remained stagnant but domestic sales showed a healthy
growth of 55% by achieving a turnover of Rs. 26.83 Crores as against
Rs. 17.29 Crores achieved during the previous financial year. In order
to exploit the Low Volume and High margin products in Bulk Drug
segment, your Company has commissioned a Kilo Lab facility at
Bangalore, during the Financial Year 2013-14, which will contribute to
growth in the years to come.
(iv) Overall Export Performance:
The over all exports of your Company during the year under review
increased to Rs. 107.66 crores from Rs. 86.04 crores achieved during
the previous financial year, thus registering a growth of 25%. Your
Company for the first time crossed a milestone of Rs. 100 crore in
revenues from Export sales.
Your Company continues to be a consistent net foreign exchange earner
to the country''s economy.
(v) Others:
Revenue from sales to Govt. Institutional business registered a
turnover of Rs. 2.88 crores during the year under review as against Rs.
5.11 crores achieved during the previous financial year. This negative
growth in turnover is mainly due to Company''s focus shift towards
export markets. The Ayurvedic products Division has contributed to a
turnover of Rs. 3.19 crores, during the year under review as against
Rs. 1.92 crores registered during the previous year. Your Company is
planning to give more focus to this division to improve its share in
the overall revenue contribution, in the years to come.
4. HEALTH CARE BUSINESS
As part of its forward integration plans, Your Company has ventured
into the Health Care Segment by starting its maiden health care clinic
in Bangalore which is aimed at providing holistic diabetes care to the
patients. Your Company plans to expand its network based on the success
of this pilot project.
5. RESEARCH & DEVELOPMENT
The Research and Development division of our Company has continued its
activity in the field of development and standardization of pathways
for the manufacture of novel and high value active pharmaceutical
ingredients. The efficient pathways thus devised have resulted in
reaching commercial production levels of these drugs to meet the needs
of the international markets.
The products developed by the R&D division, when they enter the
manufacturing stream, are backed by extensive documentation of data
pertaining to the control of the quality of the drug. The quality and
purity of these products are established by recourse to extensive and
sophisticated analytical methodology. The R&D division works in tandem
with the Quality Control Department in the development of stringent
analytical procedures and protocols.
The quality of the drugs that are offered to our customers being of
such high order that there is ready acceptance of our products in the
international markets. There is continuing and growing demand for
products of your Company. New products in the therapeutic segments of
anti allergic, psychiatrics and for the treatment of inflammatory
disorders are being introduced in the near future in the commercial
market. These products are of direct result of R&D efforts in this
direction.
The Board of Directors of the Company has in principle approved setting
up of a research foundation called as ''Bal Research Foundation'' with an
objective of doing research and study in allopathic, ayurvedic and
herbal formulations. This foundation is being formed exclusively as non
profit organisation with an intention for promoting the wellbeing of
the society at large.
6. AUDIT COMMITTEE
The Audit Committee, a sub-committee of Board consists of Dr. G.S.R
Subba Rao, Independent Director, Mr. Shrenik Siroya, Non-executive
Director, Mr. Pramod Kumar S. Independent Director and Mr. S. Pranesh,
Director who is nominee of EXIM Bank, the term loan lender to the
Company.
This Committee is chaired by Dr. G.S.R Subba Rao. Audit Committee has
been discharging its duties under SEBI Guidelines read with the Listing
Agreement. The said Committee is also functioning as Audit committee
under Section 292A of the Companies Act, 1956.
7. AUDITORS'' REPORT
There are no qualifications or adverse remarks by the auditors in their
report.
8. INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY
Your Company has an adequate system of internal controls with clearly
defined authority limits. They ensure that the Company''s assets are
protected against loss from unauthorised use or disposition and all
transactions are authorised, recorded and reported in conformity with
generally accepted accounting principles. These systems are designed to
ensure accuracy and reliability of accounting data, promotion of
operational efficiency and adherence to the prescribed management
policies. These policies are periodically reviewed to meet current
business requirements.
Internal Audit is carried out by Messrs., Manjunath & Co. a firm of
independent Chartered Accountants. They interact with the Audit
Committee and have reported to the Directors that there is adequate
internal control systems in place in respect of the areas of audit
carried out by them.
9. DIRECTORS'' RESPONSIBILITY STATEMENT
In compliance to the provisions of Section 2I7(2AA) of the Companies
Act, 1956, your Directors wish to confirm with reference to statement
of Accounts for the financial year ended on 31.03.2014:
(i) that in preparing the Annual Accounts, all the applicable
Accounting Standards have been followed;
(ii) that the Directors had selected such accounting policies and
applied them consistently and made judgements and estimates that are
reasonable and prudent so as to give a true and fair view of the state
of affairs of the Company at the end of the Financial Year and of the
P&L of the Company for that period.
(iii) that the Directors have taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the
provisions of the Act for safeguarding the assets of the Company and
for preventing/detecting fraud and other irregularities;
(iv) That the Directors have prepared the annual accounts on ''going
concern'' basis.
(v) That the Directors have laid down internal financial controls to be
followed by the Company and that such internal financial controls are
adequate and operating effectively.
(vi) That the Directors have devised proper systems to ensure
compliance with the provisions of all applicable laws and that such
systems were adequate and operating effectively.
10. SUBSIDIARY COMPANIES
As on 31.03.2014, your Company has no subsidiaries, either wholly owned
or otherwise, Indian or overseas.
11. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE
EARNINGS AND FOREIGN EXCHANGE OUTGO
As per provisions of Section 2I7(I)(e) of the Companies Act, I956, read
with the Companies (Disclosure of Particulars in the Report of the
Board of Directors) Rules, 1988, details relating to the Conservation
of Energy and Technology Absorption & Foreign Exchange Earnings and
Outflow are given in Annexure I which forms part of the Directors''
Report.
12. PARTICULARS OF EMPLOYEES
A statement of particulars of employees as required under Section
2I7(2A) of the Companies Act, 1956, is given as Annexure II and forms
part of this report.
13. PUBLIC DEPOSITS
As on date of the Report, the Company has not accepted any deposits
from public.
14. DIRECTORS
Dr. G.S.R Subba Rao and Mr. Pramod Kumar S, Directors, retire by
rotation and being eligible, offer themselves for re-appointment. In
terms of the requirements of the new Companies Act, 2013, their
appointments as Independent Directors are proposed under Special
Business.
Mr. Shrenik Siroya, Non Independent Director, retires by rotation as
per the new Companies Act, 2013 and being eligible, offers himself for
re-appointment.
Mr. Shailesh Siroya was reappointed as Managing Director by the Board
for a period of next 5 (five) years i.e. from 01.08.2014 to 31.07.2019,
subject to the approval by the Shareholders.
15. AUDITORS
Messrs T D. Jain & DI Sakaria Chartered Accountants, Statutory Auditors
of the Company retire at the Annual General Meeting and being eligible,
offer themselves for re-appointment.
16. COST AUDIT
Pursuant to Section 233B of the Companies Act, 1956, the Central
Government has prescribed Cost Audit of the Company''s Formulations as
well as Bulk Drug Business.
The Board has appointed Mr. M.R. Krishna Murthy as Cost Auditor of the
Company for the financial year 2013-14 for cost audit of both
Formulations and Bulk Drug units of the Company. The cost audit report
will be submitted to authorities within the time limit prescribed for
the purpose.
17. CORPORATE GOVERNANCE AND ADDITIONAL INFORMATION TO SHARE HOLDERS
A detailed report on the Corporate Governance System and practices of
the Company are given in a separate section in this Annual Report.
Detailed information for the shareholders is given in Additional
Shareholders information section.
Outstanding Un-paid dividend amount for the financial year 2005-06 that
is due for transfer to the Investor Education and Protection Fund has
been duly transferred, during the year.
18. HUMAN RESOURCES
The human resources of the Company continue to contribute its share in
the growth of the Company. Human Resource agenda of the company for the
year continued to focus on building a robust talent pipeline, enhancing
individual and organizational capabilities for future readiness,
driving greater employee engagement, and strengthening employee
relations though progressive people management.
There was no complaint lodged by any woman employee under Sexual
Harassment of Women at Workplace (Prevention, Prohibition and
Redressal) Act, 2013, with the Company during the period under report.
19. CEO & CFO CERTIFICATION
The Board has acknowledged the Managing Director as the CEO of the
Company and AVP Finance & Accounts as the CFO for the purpose of
compliance under the Listing Agreement. The CEO and CFO have certified
to the Board, in terms of Clause 49 of the Listing Agreement that the
financial statements present a true and fair view of the company''s
affairs and are in compliance with accounting standards.
20. INSURANCE COVERAGE
The Board of Directors reports that your Company has adequate and
comprehensive insurance cover on all the movable and immovable assets
of the Company.
21. APPRECIATION
Your Directors place on record their sincere appreciation of
significant contributions made by the employees through their
dedication, hard work and commitment. Your directors also place on
record their sincere thanks to the trust reposed on the Company by the
medical fraternity and the patients. Your board also acknowledge the
support extended to your Company by Canara Bank, Punjab National Bank,
EXIM Bank, other Banks & financial institutions, government agencies,
shareholders and investors at large. Your Company look forward to the
continued support from all the quarters in its endeavour to help people
lead healthier lives.
For and on behalf of the Board of Directors
Bangalore Dr. S. Prasanna Shailesh D Siroya
28th May, 2014 Whole Time Director Managing Director
Mar 31, 2013
The Directors have pleasure in presenting the 26th Annual Report
together with the Audited Accounts of the Company for the financial
year ended on 31st March, 2013.
1. FINANCIAL RESULTS
(Rs.in Crores)
Particulars 2012-13 2011-12
1) Total Income from operations 150.25 142.25
2) Earnings before Interest, Tax, 17.88 15.89
Depreciations Amortisation
Less:
Depreciations Amortisation 4.81 4.13
Finance cost 7.98 7.39
Profit/(Loss)before taxation and prior
period adjustment 5.09 4.37
Less:
3) Current Tax
4) Deferred Tax 0.82 0.61
5) Extra Ordinary/Non Recurring items
6) Prior year Adjustments (0.01) -
7) Profit after tax for the year 4.28 3.76
Add:
8) Profits loss account balance at the 11.80 8.04
beginning of the year
9) Profit/(Loss) made available for 16.08 11.80
appropriation
Less:
10) Proposed Dividend on Equity Shares 0.79 0.00
11) Tax on Dividend 0.13 0.00
12) Balance Carried to Balance sheet 15.16 11.80
Note : Previous year''s expenses have been regrouped to confirm this
year''s classification.
2. DIVIDEND & APPROPRIATIONS
Your directors are pleased to recommend payment of dividend of Re.
0.75/- (i.e 7.5%) on each equity share of Rs. 10 each, thereby absorbing
an amount of Rs. 0.92 crores including dividend distribution tax of Rs.
0.13 crores. The balance amount of profit is retained as surplus in the
statement of profit and loss, forming part of reserves and surplus.
3. BUSINESS OPERATIONS
(i) Turnover and Net profit
Duringthe financial year 2012-13, your Company has achieved an gross
turnover of Rs. 150.25 cores as against Rs. 142.25 crores achieved during
the previous financial year, thus registering a moderate growth of
5.62%.
The net profit after tax of the Company during the financial year
2012-13 stands at Rs. 4.28 Crores as against the net profit of Rs. 3.75
crores achieved in the previous financial year, 201
l-l2.Theprofitofthefinancialyear20l l-l2includeaone time gain of Rs. 0.88
crores on sale of fixed assets (building). If the same is excluded for
comparison purpose, the net profit growth during the current financial
year stands at 49% over the previous year.
(ii) Formulations
The turnover from export formulations during the year under review
stands at Rs. 48.47 crores as against Rs. 39.42 crores achieved during the
previous financial year thus registering a good growth of 22.96%. The
growth in export was due to penetration in new virgin markets like Lain
America, African and South East Asian Countries with both the plants at
Bangalore and Uttaranchal contributing with higher volume of production
to meet the demand.
In the domestic market, Branded formulations of the company, consisting
of mainly Diabetic and Cardiac drugs have contributed to a revenue of Rs.
24.63 crores during the year under review as against Rs. 24.09 crores
achieved during the previous year, Considering the overall sluggishness
in the domestic market, the performance may be considered satisfactory.
(iii) Bulk Drugs
Bulk drug business continues to be the major contributor of revenue,
with a revenue of Rs. 54.86 crores during the year under review as
compared to Rs. 53.01 crores achieved during the previous financial year,
thereby registering the moderate growth of 3.48%. Exports of bulk drug
during the year under review stands at Rs. 37.57 crores as against Rs.
36.44 crores during the previous financial year.
(iv) Overall export performance
The over all exports of your Company during the year under review
increased to Rs. 86.04 crores from Rs. 75.85 crores achieved during the
previous financial year, thus registering a growth of 13.43%
Your company continues to be a consistent net foreign exchange earner
to the country''s economy.
(v) Others
Revenue from sales to Govt. Institutional business registered a
turnover of Rs. 5.1 I crores during the year under review as against Rs.
8.14 crores achieved during the financial year 201 1-12. This negative
growth in turnover is mainly due to company''s focus shift towards
export markets. The Ayurvedic products Division has contributed to a
turnover of Rs. 1.92 crores, during the year under review as against Rs.
1.73 crores registered during the previous year. Your company is
planning to give more focus to this division to improve its share in
the overall revenue contribution in the years to come.
5. RESEARCH & DEVELOPMENT
The Research and Development division of our Company has continued its
activity in the field of development and standardization of pathways
for the manufacture of novel and high value active pharmaceutical
ingredients. The efficient pathways thus devised have resulted in
reaching commercial production levels of these drugs to meet the needs
of the international market.
The products developed by the R&D division, when they enter the
manufacturing stream, are backed by extensive documentation of data
pertaining to the control of the quality of the drug. The quality and
purity of these products are established by recourse to extensive and
sophisticated analytical methodology. The R&D division works in tandem
with the Quality Control Department in the development of stringent
analytical procedures and protocols.
The quality of the drugs that are offered to our customers being of
such high order that there is ready acceptance of our products in the
international markets. There is continuing and growing demand for
products of your Company. Very new products in the therapeutic segments
of anti allergic, psychiatrics and for the treatment of inflammatory
disorders are being introduced in the near future in the commercial
market. These products are of direct result of R&D efforts in this
direction.
6. AUDIT COMMITTEE
The Audit Committee, a sub-committee of Board consists of Dr. G.S.R
Subba Rao, Independent Director, Mr. Shrenik Siroya, Non- executive
Director, Mr.Pramod Kumar S Independent Director and Mr. Ajit Kumar,
Director who is nominee of EXIM Bank, the lender to the company.
This Committee is Chaired by Dr.G.S.R Subba Rao. Audit Committee has
been discharging its duties under SEBI Guidelines read with the listing
agreement. The said Committee is also functioning as Audit committee
under section 292A of the Companies Act, 1956.
7. AUDITORS''REPORT
There are no adverse qualifications or remarks by the Auditors'' in the
Auditors''Report.
8. INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY
Your Company has an adequate system of internal controls with clearly
defined authority limits. They ensure that the Company''s assets are
protected against loss from unauthorised use or disposition and all
transactions are authorised, recorded and reported in conformity with
general accepted accounting principles. These systems are designed to
ensure accuracy and reliability of accounting data, promotion of
operational efficiency and adherence to the prescribed management
policies. These policies are periodically reviewed to meet current
business requirements.
Internal Audit is carried out by Messrs., Manjunath & Co. a firm of
independent Chartered Accountants. They interact with the Audit
Committee and have reported to the Directors that there is adequate
internal control systems in place in respect of areas of audit carried
out by them.
9. DIRECTORS'' RESPONSIBILITY STATEMENT
In compliance to the provisions of Section 2I7(2AA) of the Companies
Act, 1956, your Directors wish to confirm with reference to statement
of Accounts for the financial year ended on 31.03.2013:
(i) that in preparing the Annual Accounts, all applicable Accounting
Standards have been followed;
(ii) that the accounting policies adopted are consistently followed and
the judgements or estimates made are reasonable and prudent so as to
give a true and fair view of the state of affairs of the company at the
end of the financial year and of the profit and Loss Account of the
Company for the financial year;
(iii) that the Directors have taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the
provisions of the Act for safeguarding the assets of the Company and
for preventing/detecting fraud and other irregularities;
(iv) That the Directors have prepared the annual accounts on ''going
concern''basis.
10. SUBSIDIARY COMPANIES
As on 3 1.03.2013, your company has no subsidiaries, either wholly
owned or otherwise, Indian or overseas.
11. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE
EARNINGS AND FOREIGN EXCHANGE OUTGO
As per provisions of Section 217( I )(e) of the Companies Act, 1956,
read with the Companies (Disclosure of Particulars in the Report of the
Board of Directors) Rules, 1988, details relating to the Conservation
of Energy and Technology Absorption and Foreign
Exchange Earnings and Outflow are given in Annexure I which forms part
of the Directors''Report.
12. PARTICULARS OF EMPLOYEES
A statement of particulars of employees as required under Section
217(2A) of the Companies Act, 1956, is given as Annexure II and forms
part of this report.
13. PUBLIC DEPOSITS
As on date of the Report, the Company has not accepted any deposits
from public.
14. DIRECTORS
Dr. S Prasanna and Mr. Pramod Kumar. S, Independent Directors of the
Company are retiring by rotation at the ensuing Annual General Meeting
and being eligible, offer themselves for reappointment. Your Directors
recommend their reappointment.
15. AUDITORS
Messrs TD.jain & Dl Sakaria (eststwhile) M/s Ostawal & Jain, Chartered
Accountants, Statutory Auditors of the Company retire at the Annual
General Meeting and being eligible offer them selves for
re-appointment.
16. COST AUDIT
Pursuant to Section 233B of the Companies Act, 1956, the Central
Government has prescribed Cost Audit of the Company''s Formulations as
well as Bulk Drug Units.
The Board has appointed Mr. M.R Krishna Murthy as Cost Auditor of the
Company for the financial year 2012-13 for cost audit of both
Formulation and Bulk Drug units of the Company and the Company has also
obtained the central government approval for the same. The Cost Audit
is under progress and the Company will submit the Cost Auditor''s report
for FY 2012-13, to the Central Government soon.
17. CORPORATE GOVERNANCE AND ADDITIONAL INFORMATION TO SHARE HOLDERS
A detailed report on the Corporate Governance System and practices of
the Company are given in a separate section in this Annual Report.
Detailed information for the shareholders is given in Additional
Shareholders information section.
Outstanding Un-paid dividend amount for the year 2004-05 that is due
for transfer to the Investor Education and Protection Fund has been
duly transferred, during the year.
18. HUMAN RESOURCES
The human resources of the Company continue to contribute its share in
the growth of the Company. Human Resource agenda of the company for the
year continued to focus on building a robust talent pipeline, enhancing
individual and organizational capabilities for future readiness,
driving greater employee engagement, and strengthening employee
relations though progressive people management.
19. CEO &CFO CERTIFICATION
The Board has acknowledged the Managing Director as the CEO of the
Company and G.M Finance as the CFO for the purpose of compliance under
the Listing Agreement. The CEO & CFO have certified to the Board, in
terms of Clause 49 of the Listing Agreement that the financial
statements present a true and fair view of the company''s affairs and
are in compliance with accounting standards.
20. INSURANCE COVERAGE
The Board of Directors reports that your Company has adequate and
comprehensive insurance cover on all the movable and immovable assets
of the Company.
21. APPRECIATION
Your Directors place on record their sincere appreciation of
significant contributions made by the employees through their
dedication, hard work and commitment. Your directors also places on
record its thanks on the trust reposed on the Company by the medical
fraternity and the patients. We also acknowledge the support extended
to us by Canara Bank, Punjab National Bank, EXIM Bank, and other Banks
& financial institutions, government agencies, shareholders and
investors at large. We look forward to having the same support in our
endeavor to help people lead healthier lives.
For and on behalf of the Board of Directors
Bangalore Dr. S Prasanna Shailesh Siroya
27th May, 2013 Non-Executive Director Managing Director
Mar 31, 2012
The Directors have pleasure in presenting the 25th Annual Report
together with the Audited Accounts of the Company for the financial
year ended on 31st March, 2012.
1. FINANCIAL RESULTS:
(Rs. in Lakhs)
Particulars 2011-12 2010-11
1) Total Income 14,224.60 11,664.84
2) Earnings before Interest , Tax, 1588.51 1131.76
Depreciation & Amortisation
Less :
Depreciation & Amortisation 413.08 342.36
Finance cost 729.91 679.13
Profit /(Loss)before taxation and prior
period adjustment 445.52 110.27
Less :
3) Provision for taxation 8.95 4.53
4) Deferred Tax 60.75 58.67
5) Extra Ordinary / Non Recurring items - -
6) Prior year adjustments 0.12 (0.16)
7) Profit after Tax 375.70 47.23
Add:
8) Profit & loss account balance at the 804.53 809.56
beginning of the year
9) Profit /(Loss) made available for 1,180.23 856.79
appropriation
Less:
10) Proposed Dividend on Equity Shares - -
11) Tax on Dividend - -
12) Balance Carried to Balance sheet 1,180.23 856.79
Note: Previous year's income has been regrouped in line with that of
the year under review for comparison. The opening balance of P & L has
been reduced during the year consequent upon merger of Basava Chem
Ltd., with the Company.
2. DIVIDEND:
In view of the capex plans and to facilitate expansion programs under
consideration, your Directors have decided not to recommend payment of
dividend for the financial year 2011-12.
4. BUSINESS OPERATIONS:
During the financial year 2011-12, your Company has achieved a total
turnover of Rs 142.25 crores as against Rs. 116.65 crores achieved during
the previous year 2010-11, thus registering a growth of 21.95%.
With this increase in turnover, the net profit after tax of the Company
during 2011-12 has increased substantially to Rs. 3.76 crores as against
the net profit of Rs. 0.47 crore achieved in the previous year, 2010-11.
The bulk drug business continues to dominate, as the total sales on
this segment has increased from Rs. 46.20 crores in 2010-11 to Rs. 53.01
crores during the year 2011-12. The products mix during the year
2011-12 improved with higher sale of high value items in addition to
our regular API.
Exports of Bulk Drugs has registered a growth of 16.05% during the year
under review with a turnover of Rs. 36.44 crores as against Rs. 31.40
crores achieved during the previous financial year.
The export formulations division registered a growth of 6.71% by
increasing its turnover from Rs. 36.94 crores in the previous year to Rs.
39.42 crores during the year under review. Your Company expanded its
presence in many new global markets such as Latin America, many African
countries, South East Asia etc.
Your Company's branded formulations Divisions mainly consisting of
"Diabetic" and "Cardiac" Products made a net sale of Rs. 24.09 crores
during 2011.12 as against Rs. 19.58 crores during the previous year,
thereby strengthening the Company's presence in the domestic market.
The over all exports of your Company during the year under review has
increased to Rs. 75.85 crores from Rs. 66.48 crores achieved during the
previous year.
Supplies to Govt. Institutional business registered a turnover of Rs.
8.14 crores during the year, as against Rs. 6.44 crores during the
previous year and the Ayurvedic products Division has achieved a turn
over of Rs 1.73 crores, during the year under review as against Rs. 1.94
crores achieved during the previous financial year.
Your Company has also won the Best Exporter award from the Sri Lankan
Government for the Year 2011-12 for supply of drugs and medical
equipments to Sri Lanka Pharmaceutical Corporation, a Government of Sri
Lanka enterprise.
5. RESEARCH & DEVELOPMENT:
The Research and Development division of your Company continued its
activities in the field of development and standardization of pathways
for the manufacture of novel and high value active pharmaceutical
ingredients. The clear pathways thus established have resulted in the
scale up of production levels of these drugs to meet the needs of the
international market.
The products developed by the R&D division, when they enter the
manufacturing stream, are backed by extensive documentation of data
pertaining to the control of the quality of the drug. The quality and
purity of these products are established by recourse to extensive and
sophisticated analytical methodology. The R&D division works in tandem
with the Quality Control Department in the development of stringent
analytical procedures and protocols.
The quality of the drugs your Company offers to its customers being of
such high order, there is ready acceptance of these products in the
international markets. There is continuing and growing demand for
products of your Company. New products in the therapeutic segments of
antihistamines, anxiolytics and for the treatment of neurological
disorders are being introduced in the near future in the commercial
market. These products are of direct result of R&D efforts in this
direction.
6. AUDIT COMMITTEE:
The Audit Committee consisted of Dr. G.S.R. Subba Rao, Independent
Director as Chairman, Mr. Ajit Kumar, nominee Director of EXIM Bank and
Mr. Shrenik Siroya, Non-executive Director; Mr. Pramod Kumar. S who is
Independent Director was inducted into the Committee as member, with
effect from 10.08.2012. The Audit Committee has been discharging its
duties under SEBI Guidelines read with the Listing Agreement. The said
Committee is also functioning as Audit Committee under Section 292A of
the Companies Act, 1956.
7. AUDITORS' REPORT
There are no adverse qualifications or remarks in the Auditors' Report.
However, regarding the outstanding un-paid dividend amount for the year
2003.04 of Rs. 1,84,828 which was due for transfer to the Investor
Education and Protection Fund, as mentioned in the Auditors' Report, it
is hereby confirmed that the amount has since been transferred to the
said Fund.
8. INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY:
Your Company has an adequate system of internal controls with clearly
defined authority limits. They ensure that the Company's assets are
protected against loss from unauthorised use or disposition and all
transactions are authorised, recorded and reported in conformity with
generally accepted accounting principles. These systems are designed to
ensure accuracy and reliability of accounting data, promotion of
operational efficiency and adherence to the prescribed management
policies. These policies are periodically reviewed to meet current
business requirements.
Internal Audit is carried out by Messrs. Manjunath & Co. Bangalore, an
independent firm of Chartered Accountants. They interact with the
Audit Committee and have reported to the Directors that there is
adequate internal control systems in respect of areas carried out by
them.
9. DIRECTORS' RESPONSIBILITY STATEMENT:
In compliance to the provisions of Section 2I7(2AA) of the Companies
Act, 1956, your Directors wish to confirm with reference to statement
of Accounts for the financial year ended on 31.03.2012:
(i) that in preparing the Annual Accounts, all applicable Accounting
Standards have been followed;
(ii) that the accounting policies adopted are consistently followed and
the judgements or estimates made are reasonable and prudent so as to
give a true and fair view of the state of affairs of the Company at the
end of the financial year and of the profit and Loss Account of the
Company for the financial year ;
(iii) that the Directors have taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the
provisions of the Act for safeguarding the assets of the Company and
for preventing/detecting fraud and other irregularities;
(iv) That the Directors have prepared the annual accounts on 'going
concern' basis.
10. SUBSIDIARY COMPANIES:
The Amalgamation proceedings of Basav Chem limited, with Bal Pharma
Limited was approved by Honourable High Court of Karnataka vide COP No
90/2010 and 89/2010. As on 31.03.2012 the Company has no subsidiaries,
either wholly owned or otherwise. Hence, the financial results of the
Company for the year under review and the results pertaining to the
previous year, are not entirely comparable.
11. PARTICULARS OF EMPLOYEES:
There was no employee drawing remuneration falling within the limits
prescribed under Section 2I7(2A) of the Companies Act, 1956.
12. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE
EARNINGS AND FOREIGN EXCHANGE OUTGO:
As per provisions of Section 217(I)(e) of the Companies Act, I956, read
with the Companies (Disclosure of Particulars in the Report of the
Board of Directors) Rules, I988, details relating to the Conservation
of Energy and Technology Absorption and Foreign Exchange Earnings and
Outflow are given in Annexure I, which is forming part of the Directors
Report.
13. PUBLIC DEPOSITS:
As on date of the Report, the Company has not accepted any public
deposits.
14. DIRECTORS:
Dr. G. S. R Subba Rao and Mr. Shrenik Siroya, Directors retire by
rotation at the 25th Annual General Meeting of the Company and being
eligible, offer themselves for reappointment. Your Directors recommend
their reappointments.
15. AUDITORS:
Messrs T. D. Jain & DI Sakaria (erstwhile Messrs Ostawal & Jain),
Chartered Accountants, Statutory Auditors of the Company retire at the
Annual General Meeting and are eligible them for appointment.
16. COST AUDIT:
Pursuant to Section 233B of the Companies Act, I956, the Central
Government has prescribed Cost Audit of the Company's Formulations
Division as well as Bulk Drug Division.
Subject to the approval of the Central Government, the Board has
appointed Mr. M.R. Krishna Murthy as Cost Auditor of the Company for
the financial year, 2011-12 for cost audit of both Formulation and Bulk
Drug divisions of the Company separately. The Cost Audit is under
progress and the Company will submit the Cost Auditor's report to the
Central Government soon.
17. CORPORATE GOVERNANCE AND ADDITIONAL INFORMATION TO SHAREHOLDERS:
A detailed report on the Corporate Governance System and practices of
the Company are given in a separate section in this Annual Report.
Detailed information for the shareholders is given in Additional
Shareholders information section.
18. HUMAN RESOURCES:
The Company's Human Resource agenda for the year focused on
strengthening four key areas: Building a robust talent pipeline,
enhancing individual and organizational capabilities for future
readiness, driving greater employee engagement, and strengthening
employee relations through progressive people management.
19. INSURANCE COVERAGE:
The Board reports that your Company has adequate insurance cover on all
the assets of the Company.
20. APPRECIATION:
Your Directors place on record their sincere appreciation of
significant contributions made by the employees through their
dedication, hard work and commitment and the trust reposed on us by the
medical fraternity and the patients. The Directors also acknowledge the
support and wise counsel extended to the Company by Canara Bank, Punjab
National Bank, EXIM Bank, State Bank of India and other Banks and
financial institutions, government agencies, shareholders and investors
at large. Your Directors look forward to having the same support in
their endeavour to help people lead healthier lives.
For and on behalf of the Board of Directors
Bangalore
Dr. S. Prasanna Shailesh Siroya
10th August, 2012 Executive Director Managing Director
Mar 31, 2010
The Directors have pleasure in presenting the 23rd Annual Report
together with the Audited Accounts of the Company for the financial
year ended on 31st March, 2010.
1. FINANCIAL RESULTS:
(Rs. in Lakhs)
Particulars 2009-10 2008-09
1) Total Income 108,15.16 10667.67
2) Profits before 195.47 598.59
Depreciation and
provision for Taxation
Less : Depreciation 285.90 188.58
Profits before (90.43) 410.01
Taxation and prior year adjustments
Less :
3) Provision for Taxation 7.33 3.52
4) Fringe Benefit Tax - 23.47
5) Deferred Tax 44.94 79.30
6) Extraordinary/ Non Recurring items - -
7) Prior year adjustment (0.18) 52.08 4.44 110.73
Add:
8) Profit & Loss Account 142.89 299.28
balance at the
beginning of the year
9) Profit made available 906.62 699.32
for appropriation
763.74 998.60
Less:
10) Proposed Dividend on - 78.62
Equity Shares
11) Tax on dividends - - 13.36 (-) 91.98
12) Balance Carried to 763.74 906.62
Balance Sheet
2. DIVIDEND:
In view of the results, your Directors have decided not to recommend
payment of dividend for the year, 2009-10.
3. MANAGEMENT DISCUSSION AND ANALYSIS:
Global Pharmaceutical Industry Challenges
The global pharmaceutical business is becoming more complicated than
ever before. Older business models are being challenged by competition;
new verticals are coming into play. There will be new developments and
alliances, as well as new opportunities and challenges. In such an
environment only the rapid, clever and nimble will win.
If present industry overview is taken in to consideration, the global
pharmaceutical market in 2010 is projected to grow 4% to 6% exceeding
US$ 825 billion. This growth will be largely driven by strong overall
growth in the emerging countries, as well as the rising influence of
healthcare access and funding on market demand. Moreover, the global
market is expected to grow at 4-7% Compound Annual Growth Rate (CAGR)
through 2013. Global pharmaceutical market value is expected to expand
to $975 plus billions by 2013.
EMERGING TRENDS:
Emerging markets are set to play a pivotal role in future
pharmaceutical success. Emerging pharmaceutical markets are typically
small. However, their rapid growth vis-ÃÂ -vis the more regulated markets
make them attractive prospects for the pharmaceutical industry. Rapidly
growing economies, increasing population and greater health awareness
combined with larger incomes to spend on healthcare will drive the
growth of pharmaceuticals in emerging markets. By 2017, IMS forecasts
revenues from emerging markets at US$ 290 billion to US$ 320 billion,
with a CAGR of 12% to 15%.
INDIAN PHARMACEUTICAL INDUSTRY:
The Indian Pharmaceutical Industry ranks as a frontrunner among the
CountryÃs science based industries with wide ranging capabilities in
the complex field of drug manufacture and technology. The industry has
been growing at an impressive CAGR in excess of 8-9%, and will touch
$10 billions by 2010.
Indian pharmaceutical industry is the worldÃs 13th largest in terms of
value and 14th in terms of volume with over all 60,000 brands in over
60 therapeutic categories. India has world class facilities and
expertise in manufacturing with the largest number of US FDA approved
manufacturing units in the world out side US. Ancillary industries are
also well developed with support available locally. Quality bulk drugs
at competitive prices are assured.
- Global pharma looks to India: Prospects for growth:
The huge potential of the Indian pharmaceuticals market is impossible
for foreign companies to ignore, given that it will be one of the top
10 sales markets by 2020. IndiaÃs population is growing rapidly, as is
its economy - creating a large middle-class able to afford western
medicines. IndiaÃs epidemiological profile is also changing and the
population is ageing, so demand is likely to increase for drugs for
cardiovascular problems, disorders of the central nervous system and
other chronic diseases such as diabetes which is increasing at an
alarming rate. The total market is expected to rise to a value of
approximately US $50 billions by 2020.
4. BUSINESS OPERATIONS:
During the year, 2009-10 your Company has achieved an over all turnover
of X 108.15 crores as against X 106.67 crores of the previous year.
Thus registering a marginal growth of 1.39% on the top line. Despite a
marginal increase in sales, the net results after tax decreased from X
2.99 crores of the previous year to a net loss of X 1.42 crores during
the current year. The main reason for the fall in net profit is
commissioning of our Uttarakhand plant, difference in product mix, and
cut-throat competition from large pharma players in Indian and
international markets.
The exports formulations division registered a growth of 42.34% by
increasing its turnover from X 22.39 crores in the previous year to X
31.87 crores in the current year. Your Company expanded its presence in
many new global markets such as Latin America and many African
countries.
The bulk drug business both domestic and exports have been very
encouraging with the growth of 44.36% as the turn over of the division
reached X 42.24 crores as against X 29.26 crores in the previous year.
Utilization of facility at Basav Chem Limited (wholly owned subsidiary
Company) has also been to its full capacity. Regular supplies of the
products are made to developed markets such as Europe, Japan, Australia
and Canada where the products are already registered. Various DMF have
been filed across the globe to increase our presence in other markets.
The over all exports of your Company increased (by 54.7%) to X 57.35
crores as against 37.07 crores during the year 2008-09.
The govt. Institutional business made a turnover of Rs 4.44 crores and
the Ayurvedic Division has made a turn over of Rs 2.04 crores during the
year 2009-10.
Your CompanyÃs branded formulations divisions mainly consisting of
Diabetic and Cardiac Products made a net sale of Rs 23.36 crores as
against Rs 35.21 crores during the last year. This reduction in sales in
branded formulation has affected the profit margins of the Company (34%
shortfall during the year). This short fall in sale is due to mass
attrition of a number of employees from major divisions of the Company.
Appropriate measures are being taken by your management to overcome the
reduction in branded formulation sales and to retain the existing
market.
5. RESEARCH & DEVELOPMENT:
The Research and Development division is actively engaged in the
development, scale-up and commercialization of processes for the
manufacture of high value APIÃs in niche areas. Production of these
products has enabled the Company to market them, both nationally and
internationally.
All the products manufactured through the processes developed by the
R&D division are backed by complete, internationally accepted,
documentation and controls. The quality and purity of these products
are established and maintained by sophisticated analytical methods and
protocols developed in-house by the R&D and QC divisions.
The ready acceptance of our products in the international market is a
clear indicator of their high quality. This is further reinforced by
tight quality controls at every stage of the manufacturing process,
leading to excellent quality characteristics in our APIs.
All this developmental work has resulted in the generation of valuable
intellectual property (IP) which the Company is now in the process of
patenting. Simultaneously, Bal Pharma has made a beginning in the
development of new chemical entities and some promising leads have been
obtained in this direction.
6. AUDIT COMMITTEE:
The Audit Committee, a sub-committee of the Board consists of Mr. David
Rasquinha (nominee Director of EXIM Bank), Dr. G. S. R. Subba Rao,
Independent Director and Mr. Shrenik Siroya, Non-Executive Director.
This Committee headed by Dr.G.S.R Subba Rao, has been discharging its
duties under SEBI Guidelines read with the Listing Agreement. The said
Committee is also functioning as Audit Committee under Section 292A of
the Companies Act, 1956.
7. INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY:
Your Company has an adequate system of internal controls with clearly
defined authority limits. They ensure that the CompanyÃs assets are
protected against loss from unauthorised use or disposition and all
transactions are authorised, recorded and reported in conformity with
generally accepted accounting principles. These systems are designed to
ensure accuracy and reliability of accounting data, promotion of
operational efficiency and adherence to the prescribed management
policies. These policies are periodically reviewed to meet current
business requirements.
Internal Audit is carried out by Messrs. Ishwar & Gopal an independent
firm of Chartered Accountants. They interact with the Audit Committee
and have reported to the Directors that there is adequate internal
control systems in respect of areas carried out by them.
8. DIRECTORSÃ RESPONSIBILITY STATEMENT:
In compliance to the provisions of Section 217(2AA) of the Companies
Act, 1956, your Directors wish to confirm with reference to statement
of Accounts for the financial year ended 31.03.2010:
(i) that in preparing the Annual Accounts, all applicable Accounting
Standards have been followed;
(ii) that the accounting policies adopted are consistently followed and
the judgements or estimates made are reasonable and prudent so as to
give a true and fair view of the state of affairs of the Company at the
end of the financial year and of the Profit and Loss Account of the
Company for the financial year ;
(iii) that the Directors have taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the
provisions of the Act for safeguarding the assets of the Company and
for preventing/detecting fraud and other irregularities;
(iv) That the Directors have prepared the annual accounts on going
concernà basis.
9. SUBSIDIARY COMPANIES:
The Company had two wholly owned Subsidiary Companies during the
financial year, 2009-10. One of the subsidiary companies, Novosynth
Research Labs Private Limited applied for striking off its name from
the register under Section 560 of the Companies Act,1956 and the
Amalgamation proceedings of Basav Chem Limited with Bal Pharma Limited
is before the Honourable High Court of Karnataka.
Statement pursuant to Section 212 of the Companies Act, 1956, relating
to CompanyÃs interest in subsidiary company, Basav Chem Limited is as
given in Annexure I forming part of the Directorà Report.
10. PARTICULARS OF EMPLOYEES:
A statement of particulars of employees as required under Section
217(2A) of the Companies Act, 1956, is given as Annexure II and forms
part of this report.
11. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE
EARNINGS AND OUTGO:
As per provisions of Section 217(1)(e) of the Companies Act, 1956, read
with the Companies (Disclosure of Particulars in the Report of the
Board of Directors) Rules, 1988, details relating to the Conservation
of Energy and Technology Absorption and Foreign Exchange Earnings and
Outgoings are given in Annexure forming part of the Directors Report.
12. PUBLIC DEPOSITS:
As on date of the Report, the Company has not accepted any public
deposits.
13. DIRECTORS:
As on date, your Board consists of 6 (six) Directors, 3 (three) of whom
are Non-Executive Directors and of which 2 (two) are Independent
Directors. 1 (one) of who is Nominee Director of Export Import Bank of
India. 2 (two) of whom are Executive Directors. Mr. Shrenik Siroya,
Non-Executive Director and Dr. G.S.R. Subba Rao, Independent Director
of the Company who retire by rotation at the 23rd Annual General
Meeting of the Company and being eligible, offer themselves for
reappointment. Your Directors have pleasure in recommending their
reappointments.
14. AUDITORS:
Messrs Ostawal & Jain, Chartered Accountants, Auditors of the Company,
retire at the Annual General Meeting and are eligible for
re-appointment.
15. COST AUDIT:
Pursuant to Section 233B of the Companies Act, 1956, the Central
Government has prescribed Cost Audit of the CompanyÃs Formulations
Division.
Subject to the approval of the Central Government, the Board has
appointed Mr. G.I. Srinivasamurthy as Cost Auditor of the Company for
the financial year, 2010-11. The Cost Audit is under process and the
Company will submit the Cost Auditorsà Report to the Central Government
in time.
16. EMPLOYEE STOCK OPTION SCHEME:
Pursuant to the provisions of Guideline 12 of the Securities and
Exchange Board of India (Employee Stock Option Scheme and Employee
Stock Purchase Scheme), Guidelines, 1999, as amended, the details of
stock options as on 31st March, 2010 under the ÃBal Pharma Limited
Employees Stock Option Scheme, 2006à is set out in the Annexure à III
to the Directors Report.
17. CORPORATE GOVERNANCE AND ADDITIONAL INFORMATION TO SHARE HOLDERS:
A detailed report on the Corporate Governance System and practices of
the Company are given in a separate section in this Annual Report.
Detailed information for the shareholders is given in Additional
Shareholders information section.
18. INSURANCE COVERAGE:
The Board reports that your Company has adequately insured all the
assets of the Company.
19. APPRECIATION:
Your Directors place on record their sincere appreciation for
significant contribution made by the employees through their
dedication, hard work and commitment and the trust reposed on us by the
medical fraternity and the patients. Your Board also acknowledges the
support and wise counsel extended by Canara Bank, Punjab National Bank,
Exim Bank, State Bank of Indore and other Banks and financial
institutions, government agencies, shareholders and investors at large.
The Directors look forward to having the same support in the our
endeavor to help people lead healthier lives.
For and on behalf of the Board of Directors
Bangalore Dr. S. Prasanna Shailesh Siroya
9th August, 2010 Executive Director Managing Director